An important bit of news has surfaced online this weekend about the heralded company Samumed.
Samumed will be presenting “Safety, Tolerability and Efficacy of a Topical Treatment (SM04554) for Androgenetic Alopecia (AGA): Results from a Phase 2 Trial” on March 5th, 2016 at the 74th Annual Meeting of the American Academy of Dermatology. The entire conference will be held from March 4th-8th in Washington D.C. at the Walter E. Washington Convention Center. The thought of attending the conference is perhaps intriguing after learning about this presentation, however, if you want to make that happen tickets go for $2,220 for members of the public. Not to worry though, Samumed released the results from it’s last conference presentation (WCHR 2015) on their website a few days after the completion of that event.
The good news is March 5th is not too far away and the fact that Samumed wants to be on stage to present their Phase II results is a good thing. Typically companies do that when the proceedings will be in their favor. Samumed continues to move right along and we’re all holding out cups of gatorade for them.